Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongji Mu

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biometrical Journal. Biometrische Zeitschrift|May 24, 2018
Predicting events in clinical trials using two time-to-event outcomesRongji Mu, Jin Xu
BMC Medical Research Methodology|October 1, 2022
A dose-finding design for phase I clinical trials based on Bayesian stochastic approximationJin Xu, Dapeng Zhang, Rongji Mu
Statistics in Medicine|October 23, 2020
A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trialsRongji Mu, Haitao Pan, Guoying Xu
Biometrics|June 19, 2026
A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomesWentao Yang, Rongji Mu, Zhangsheng Yu
Pharmaceutical Statistics|January 21, 2021
A Bayesian adaptive design for biosimilar trials with time-to-event endpointSheferaw Y Belay, Rongji Mu, Jin Xu
BMC Medical Research Methodology|December 13, 2021
An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trialsRongji Mu, Zongliang Hu, Guoying Xu, et al.
Statistical Methods in Medical Research|May 14, 2026
A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimizationXian Shi, Jiangyan Zhao, Jin Xu, et al.
Contemporary Clinical Trials|July 25, 2021
A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trialsRongji Mu, Guoying Xu, Guanfu Liu, et al.
Biometrics|September 10, 2024
A Bayesian latent-subgroup platform design for dose optimizationRongji Mu, Xiaojiang Zhan, Rui Sammi Tang, et al.
Statistics in Medicine|November 3, 2021
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indicationsRongji Mu, Jin Xu, Rui Sammi Tang, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biometrical Journal. Biometrische Zeitschrift|May 24, 2018
Predicting events in clinical trials using two time-to-event outcomesRongji Mu, Jin Xu
BMC Medical Research Methodology|October 1, 2022
A dose-finding design for phase I clinical trials based on Bayesian stochastic approximationJin Xu, Dapeng Zhang, Rongji Mu
Statistics in Medicine|October 23, 2020
A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trialsRongji Mu, Haitao Pan, Guoying Xu
Biometrics|June 19, 2026
A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomesWentao Yang, Rongji Mu, Zhangsheng Yu
Pharmaceutical Statistics|January 21, 2021
A Bayesian adaptive design for biosimilar trials with time-to-event endpointSheferaw Y Belay, Rongji Mu, Jin Xu
BMC Medical Research Methodology|December 13, 2021
An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trialsRongji Mu, Zongliang Hu, Guoying Xu, et al.
Statistical Methods in Medical Research|May 14, 2026
A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimizationXian Shi, Jiangyan Zhao, Jin Xu, et al.
Contemporary Clinical Trials|July 25, 2021
A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trialsRongji Mu, Guoying Xu, Guanfu Liu, et al.
Biometrics|September 10, 2024
A Bayesian latent-subgroup platform design for dose optimizationRongji Mu, Xiaojiang Zhan, Rui Sammi Tang, et al.
Statistics in Medicine|November 3, 2021
A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indicationsRongji Mu, Jin Xu, Rui Sammi Tang, et al.
Pageof 2